Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03703102
Other study ID # 4083-006
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 22, 2018
Est. completion date November 12, 2020

Study information

Verified date April 2024
Source Kyowa Kirin Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.


Recruitment information / eligibility

Status Completed
Enrollment 274
Est. completion date November 12, 2020
Est. primary completion date February 6, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Voluntarily signed informed consent to participate in the study; - Chronic AD, according to American Academy of Dermatology Consensus Criteria or the local diagnostic criteria, that has been present for at least 1 year before screening; - EASI score =16 at screening and baseline; - IGA score =3 (moderate) at both screening and baseline; - BSA =10% at both screening and baseline; - Documented recent history (within 1 year prior to screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks). Exclusion Criteria: - Current or past history of clinically significant illness(es) deemed by the Investigator to be likely to affect the study conduct and assessments. Examples include, but are not limited to, clinically significant cardiovascular (e.g., New York Heart Association [NYHA] Class III or IV), uncontrolled diabetes (HbA1c =9%), liver (e.g., Child-Pugh class B or C), renal, respiratory, hematologic, central nervous system, psychiatric, or autoimmune diseases/disorders; - Any of the following laboratory abnormalities at screening: - Serum creatinine: >1.5 mg/dL - AST or ALT: =2.5 times the upper limit of normal (ULN) - Neutrophil count: <1.5×10³/µL - Other laboratory abnormalities that may affect the completion or evaluation of the study, as judged by the Investigator; - Active malignancies, or onset or a history of treatment of malignancies within 5 years prior to informed consent (except curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KHK4083
Anti-OX40 Monoclonal Antibody KHK4083
Placebo
Matching placebo

Locations

Country Name City State
Canada Kyowa Investigational Site CA-02 Markham Ontario
Canada Kyowa Investigational Site CA-07 Quebec City Quebec
Canada Kyowa Investigational Site CA-09 Quebec City Quebec
Canada Kyowa Investigational Site CA-03 Richmond Hill Ontario
Canada Kyowa Investigational Site CA-08 Richmond Hill Ontario
Canada Kyowa Investigational Site CA-04 Sherbrooke Quebec
Germany Kyowa Investigational Site GE-13 Aachen
Germany Kyowa Investigational Site GE-07 Berlin
Germany Kyowa Investigational Site GE-14 Berlin
Germany Kyowa Investigational Site GE-08 Darmstadt
Germany Kyowa Investigational Site GE-05 Frankfurt am Main
Germany Kyowa Investigational Site GE-02 Hamburg
Germany Kyowa Investigational Site GE-11 Hannover
Germany Kyowa Investigational Site GE-01 Langenau
Japan Kyowa Investigational Site JP-17 Aichi
Japan Kyowa Investigational Site JP-27 Aichi
Japan Kyowa Investigational Site JP-24 Chiba
Japan Kyowa Investigational Site JP-08 Fukuoka
Japan Kyowa Investigational Site JP-09 Fukuoka
Japan Kyowa Investigational Site JP-12 Fukuoka
Japan Kyowa Investigational Site JP-19 Fukuoka
Japan Kyowa Investigational Site JP-26 Fukuoka
Japan Kyowa Investigational Site JP-14 Gifu
Japan Kyowa Investigational Site JP-01 Hokkaido
Japan Kyowa Investigational Site JP-02 Hokkaido
Japan Kyowa Investigational Site JP-04 Hokkaido
Japan Kyowa Investigational Site JP-29 Hokkaido
Japan Kyowa Investigational Site JP-31 Ibaraki
Japan Kyowa Investigational Site JP-10 Kagoshima
Japan Kyowa Investigational Site JP-11 Kagoshima
Japan Kyowa Investigational Site JP-05 Kanagawa
Japan Kyowa Investigational Site JP-06 Kanagawa
Japan Kyowa Investigational Site JP-21 Kanagawa
Japan Kyowa Investigational Site JP-18 Mie
Japan Kyowa Investigational Site JP-20 Miyagi
Japan Kyowa Investigational Site JP-28 Morioka
Japan Kyowa Investigational Site JP-25 Shimane
Japan Kyowa Investigational Site JP-15 Tochigi
Japan Kyowa Investigational Site JP-03 Tokyo
Japan Kyowa Investigational Site JP-07 Tokyo
Japan Kyowa Investigational Site JP-13 Tokyo
Japan Kyowa Investigational Site JP-16 Tokyo
Japan Kyowa Investigational Site JP-22 Tokyo
Japan Kyowa Investigational Site JP-23 Tokyo
Japan Kyowa Investigational Site JP-30 Tokyo
United States Kyowa Investigational Site US-10 Aurora Colorado
United States Kyowa Investigational Site US-04 Boston Massachusetts
United States Kyowa Investigational Site US-20 Charlotte North Carolina
United States Kyowa Investigational Site US-14 Clearwater Florida
United States Kyowa Investigational Site US-11 Cleveland Ohio
United States Kyowa Investigational Site US-02 Dallas Texas
United States Kyowa Investigational Site US-07 Galveston Texas
United States Kyowa Investigational Site US-19 Huntington Beach California
United States Kyowa Investigational Site US-17 Irvine California
United States Kyowa Investigational Site US-09 Los Angeles California
United States Kyowa Investigational Site US-01 New York New York
United States Kyowa Investigational Site US-08 Portland Oregon
United States Kyowa Investigational Site US-05 Santa Ana California

Sponsors (2)

Lead Sponsor Collaborator
Kyowa Kirin, Inc. Kyowa Kirin Co., Ltd.

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score In the EASI assessment, the severity of 4 elements of eczema (erythema, induration/papulation, excoriation, and lichenification) at each of 4 body regions (head and neck, trunk, upper extremities, and lower extremities) will be assessed on a scale of 0 to 3 (0 = None , 1 = Mild, 2 = Moderate, 3 = Severe). Half scores (1.5 and 2.5) are allowed, with the exception of 0.5. Any signs must be at least 1 (mild) in severity. In addition, the extent of eczema at each of the 4 body regions will be assessed on a scale of 0 to 6 (0 = 0%, 1 = 1% to 9%, 2 = 10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%). Scores calculated according to the expression "total score of 4 elements of eczema × area score of eczema" will be multiplied by 0.1 for head and neck, 0.2 for upper extremities, 0.3 for trunk, and 0.4 for lower extremities. The 4 region scores obtained will then be summed up (maximum score: 72) as EASI score. Baseline to Week 16
Secondary Achievement of 50%, 75%, or 90% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-50, EASI-75, or EASI-90) at Week 16 In the EASI assessment, the severity of 4 elements of eczema (erythema, induration/papulation, excoriation, and lichenification) at each of 4 body regions (head and neck, trunk, upper extremities, and lower extremities) will be assessed on a scale of 0 to 3 (0 = None , 1 = Mild, 2 = Moderate, 3 = Severe). Half scores (1.5 and 2.5) are allowed, with the exception of 0.5. Any signs must be at least 1 (mild) in severity. In addition, the extent of eczema at each of the 4 body regions will be assessed on a scale of 0 to 6 (0 = 0%, 1 = 1% to 9%, 2 = 10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%). Scores calculated according to the expression "total score of 4 elements of eczema × area score of eczema" will be multiplied by 0.1 for head and neck, 0.2 for upper extremities, 0.3 for trunk, and 0.4 for lower extremities. The 4 region scores obtained will then be summed up (maximum score: 72) as EASI score. Baseline to Week 16
Secondary Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score In the EASI assessment, the severity of 4 elements of eczema (erythema, induration/papulation, excoriation, and lichenification) at each of 4 body regions (head and neck, trunk, upper extremities, and lower extremities) will be assessed on a scale of 0 to 3 (0 = None , 1 = Mild, 2 = Moderate, 3 = Severe). Half scores (1.5 and 2.5) are allowed, with the exception of 0.5. Any signs must be at least 1 (mild) in severity. In addition, the extent of eczema at each of the 4 body regions will be assessed on a scale of 0 to 6 (0 = 0%, 1 = 1% to 9%, 2 = 10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%). Scores calculated according to the expression "total score of 4 elements of eczema × area score of eczema" will be multiplied by 0.1 for head and neck, 0.2 for upper extremities, 0.3 for trunk, and 0.4 for lower extremities. The 4 region scores obtained will then be summed up (maximum score: 72) as EASI score. Baseline to Week 16
Secondary Change From Baseline to Week 16 in SCORing Atopic Dermatitis (SCORAD) Score In the SCORAD assessment, the extent of AD will be calculated as the sum of the percentage of each defined body area, with a maximum score of 100% (assigned as "A" in the overall SCORAD calculation). The severity of 6 specific symptoms of AD will be assessed using the following scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, with a maximum score of 18 (assigned as "B" in the overall SCORAD calculation). Itch and sleeplessness will be assessed by subjects on a visual analogue scale (VAS), where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum score of 20 (assigned as "C" in the overall SCORAD calculation). The SCORAD score is calculated as A/5 + 7B/2 + C. The maximum possible SCORAD score is 103; higher scores indicate poorer or more severe condition. Baseline to Week 16
Secondary Percent Change From Baseline to Week 16 in SCORing Atopic Dermatitis (SCORAD) Score In the SCORAD assessment, the extent of AD will be calculated as the sum of the percentage of each defined body area, with a maximum score of 100% (assigned as "A" in the overall SCORAD calculation). The severity of 6 specific symptoms of AD will be assessed using the following scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, with a maximum score of 18 (assigned as "B" in the overall SCORAD calculation). Itch and sleeplessness will be assessed by subjects on a visual analogue scale (VAS), where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum score of 20 (assigned as "C" in the overall SCORAD calculation). The SCORAD score is calculated as A/5 + 7B/2 + C. The maximum possible SCORAD score is 103; higher scores indicate poorer or more severe condition. Baseline to Week 16
Secondary Achievement of an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction From Baseline of =2 Points at Week 16 In the IGA, the Investigator will evaluate the overall skin symptoms of subjects at each visit on a 5-point scale ranging from 0 (clear) to 4 (severe). Baseline to Week 16
Secondary Change From Baseline to Week 16 in Percent Body Surface Area of Involvement of AD (BSA) The Investigator will calculate the percentage (%) of the total body surface area affected by AD. Baseline to Week 16
Secondary Change From Baseline to Week 16 in Pruritus Numerical Rating Scale (NRS) Score The worst degree of itch experienced during 24 hours before the time point will be assessed on a Numerical Rating Scale. The degree of itch will be scored on an 11-point scale, with 0 being "no itch" and 10 being the "worst itch imaginable." Baseline to Week 16
Secondary Percent Change From Baseline to Week 16 in Pruritus Numerical Rating Scale (NRS) Score The worst degree of itch experienced during 24 hours before the time point will be assessed on a Numerical Rating Scale. The degree of itch will be scored on an 11-point scale, with 0 being "no itch" and 10 being the "worst itch imaginable." Baseline to Week 16
Secondary Change From Baseline to Week 16 in Sleep Disturbance Numerical Rating Scale (NRS) Score Daily sleep disturbance in the last 24 hours before the relevant time point will be assessed on a Numerical Rating Scale. Subjects will score the degree of their sleep disturbance on an 11-point scale ranging from 'no sleep loss' (0) to 'I cannot sleep at all' (10). Baseline to Week 16
Secondary Percent Change From Baseline to Week 16 in Sleep Disturbance Numerical Rating Scale (NRS) Score Daily sleep disturbance in the last 24 hours before the relevant time point will be assessed on a Numerical Rating Scale. Subjects will score the degree of their sleep disturbance on an 11-point scale ranging from 'no sleep loss' (0) to 'I cannot sleep at all' (10). Baseline to Week 16
Secondary Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) DLQI consists of 6 subscales (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment), which are scored from 0 to 3 on the basis of 10 questions. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more QoL is impaired. Baseline to Week 16
Secondary EASI Score at Each Time Point In the EASI assessment, the severity of 4 elements of eczema (erythema, induration/papulation, excoriation, and lichenification) at each of 4 body regions (head and neck, trunk, upper extremities, and lower extremities) will be assessed on a scale of 0 to 3 (0 = None , 1 = Mild, 2 = Moderate, 3 = Severe). Half scores (1.5 and 2.5) are allowed, with the exception of 0.5. Any signs must be at least 1 (mild) in severity. In addition, the extent of eczema at each of the 4 body regions will be assessed on a scale of 0 to 6 (0 = 0%, 1 = 1% to 9%, 2 = 10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%). Scores calculated according to the expression "total score of 4 elements of eczema × area score of eczema" will be multiplied by 0.1 for head and neck, 0.2 for upper extremities, 0.3 for trunk, and 0.4 for lower extremities. The 4 region scores obtained will then be summed up (maximum score: 72) as EASI score. 56 Weeks
Secondary Percent Change From Baseline in EASI Score at Each Time Point In the EASI assessment, the severity of 4 elements of eczema (erythema, induration/papulation, excoriation, and lichenification) at each of 4 body regions (head and neck, trunk, upper extremities, and lower extremities) will be assessed on a scale of 0 to 3 (0 = None , 1 = Mild, 2 = Moderate, 3 = Severe). Half scores (1.5 and 2.5) are allowed, with the exception of 0.5. Any signs must be at least 1 (mild) in severity. In addition, the extent of eczema at each of the 4 body regions will be assessed on a scale of 0 to 6 (0 = 0%, 1 = 1% to 9%, 2 = 10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%). Scores calculated according to the expression "total score of 4 elements of eczema × area score of eczema" will be multiplied by 0.1 for head and neck, 0.2 for upper extremities, 0.3 for trunk, and 0.4 for lower extremities. The 4 region scores obtained will then be summed up (maximum score: 72) as EASI score. 56 Weeks
Secondary Achievement of EASI-50, EASI-75, or EASI-90 at Each Time Point In the EASI assessment, the severity of 4 elements of eczema (erythema, induration/papulation, excoriation, and lichenification) at each of 4 body regions (head and neck, trunk, upper extremities, and lower extremities) will be assessed on a scale of 0 to 3 (0 = None , 1 = Mild, 2 = Moderate, 3 = Severe). Half scores (1.5 and 2.5) are allowed, with the exception of 0.5. Any signs must be at least 1 (mild) in severity. In addition, the extent of eczema at each of the 4 body regions will be assessed on a scale of 0 to 6 (0 = 0%, 1 = 1% to 9%, 2 = 10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%). 56 Weeks
Secondary SCORing Atopic Dermatitis (SCORAD) Score at Each Time Point In the SCORAD assessment, the extent of AD will be calculated as the sum of the percentage of each defined body area, with a maximum score of 100% (assigned as "A" in the overall SCORAD calculation). The severity of 6 specific symptoms of AD will be assessed using the following scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, with a maximum score of 18 (assigned as "B" in the overall SCORAD calculation). Itch and sleeplessness will be assessed by subjects on a visual analogue scale (VAS), where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum score of 20 (assigned as "C" in the overall SCORAD calculation). The SCORAD score is calculated as A/5 + 7B/2 + C. The maximum possible SCORAD score is 103; higher scores indicate poorer or more severe condition. 56 Weeks
Secondary Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Each Time Point In the SCORAD assessment, the extent of AD will be calculated as the sum of the percentage of each defined body area, with a maximum score of 100% (assigned as "A" in the overall SCORAD calculation). The severity of 6 specific symptoms of AD will be assessed using the following scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, with a maximum score of 18 (assigned as "B" in the overall SCORAD calculation). Itch and sleeplessness will be assessed by subjects on a visual analogue scale (VAS), where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum score of 20 (assigned as "C" in the overall SCORAD calculation). The SCORAD score is calculated as A/5 + 7B/2 + C. The maximum possible SCORAD score is 103; higher scores indicate poorer or more severe condition. 56 Weeks
Secondary Achievement of an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction From Baseline of =2 Points at Each Time Point In the IGA, the Investigator will evaluate the overall skin symptoms of subjects at each visit on a 5-point scale ranging from 0 (clear) to 4 (severe) 56 Weeks
Secondary Change From Baseline in Percent Body Surface Area (BSA) at Each Time Point The Investigator will calculate the percentage (%) of the total body surface area affected by AD. 56 Weeks
Secondary Pruritus Numerical Rating Scale (NRS) Score at Each Time Point The worst degree of itch experienced during 24 hours before the time point will be assessed on a Numerical Rating Scale. The degree of itch will be scored on an 11-point scale, with 0 being "no itch" and 10 being the "worst itch imaginable." 56 Weeks
Secondary Percent Change From Baseline in Pruritus Numerical Rating Scale (NRS) Score at Each Time Point The worst degree of itch experienced during 24 hours before the time point will be assessed on a Numerical Rating Scale. The degree of itch will be scored on an 11-point scale, with 0 being "no itch" and 10 being the "worst itch imaginable." 56 Weeks
Secondary Sleep Disturbance Numerical Rating Scale (NRS) Score at Each Time Point Daily sleep disturbance in the last 24 hours before the relevant time point will be assessed on a Numerical Rating Scale. Subjects will score the degree of their sleep disturbance on an 11-point scale ranging from 'no sleep loss' (0) to 'I cannot sleep at all' (10). 56 Weeks
Secondary Percent Change From Baseline in Sleep Disturbance Numerical Rating Scale (NRS) Score at Each Time Point Daily sleep disturbance in the last 24 hours before the relevant time point will be assessed on a Numerical Rating Scale. Subjects will score the degree of their sleep disturbance on an 11-point scale ranging from 'no sleep loss' (0) to 'I cannot sleep at all' (10). 56 Weeks
Secondary Dermatology Life Quality Index (DLQI) at Each Time Point DLQI consists of 6 subscales (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment), which are scored from 0 to 3 on the basis of 10 questions. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more QoL is impaired. 56 Weeks
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2